Although direct clinical evidence of systemic NAD(P) depletion during GLP-1RA therapy is lacking, experimental and observational studies suggest that NAD turnover and micronutrient status can be altered in obesity and inflammatory states [83, 85], supporting the biological plausibility of substrate-sensitive vulnerability
Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, distinguishing it from currently licensed therapies such as semaglutide and tirzepatide
Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivory
Stopping the medication may reduce ongoing dry mouth and acid exposure, but damage already done to enamel or gum tissue requires active dental treatment to address
When it comes to the medication youre taking or any other health questions you have, always consult your healthcare provider directly
How does Tirzepatide improve metabolic health